This represents a potential first for preclinical evidence of anti-tumor activity by an efficacious BCL6-targeted ...

Discover what happens to your body when you skip meals vs. follow intermittent fasting. Learn the health risks, benefits, and ...

The therapeutic landscape for hormone receptor-positive (HR+) advanced breast cancer (BC) is moving from generalized ...

For decades, the story of Alzheimer’s research has been dominated by a battle between amyloid-beta and tau amyloids, both of ...

Astrazeneca AB has disclosed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to an interleukin-1 receptor-associated kinase 4 ...

Bavdegalutamide (ARV-110) is a PROteolysis TArgeting Chimera (PROTAC®) protein degrader that recruits the cereblon-containing E3 ubiquitin ligase to direct the polyubiquitination and subsequent ...

Proteolysis targeting chimera (PROTAC) degraders are typically bifunctional with one E3 ligase ligand connected to one target protein ligand via a linker. While augmented valency has been shown with ...

The E3 ligase HOIP is vital for the NF-κB pathway and is implicated in cancer and immunity. However, it remains challenging to achieve high selectivity by directly targeting the conserved catalytic ...

Proteolysis-Targeting Chimeras (PROTACs) are emerging as a promising tool in cancer therapy, representing a novel approach to targeted protein degradation. Unlike traditional small-molecule inhibitors ...

Proteolysis targeting chimera (PROTAC)-driven internalization of antibodies targeting oncogenic cell surface receptors [abstract]. In: Proceedings of the American Association for Cancer Research ...